Core Points - Apollomics Inc. announced changes to its board of directors, including the resignation of Mr. Po-Jen Hsueh and the appointment of Dr. Ya-Chi (Claudia) Huang to fill the vacancy [1][2] - The current board now consists of seven members, with Dr. Huang also taking over Mr. Hsueh's roles on the Audit Committee and Nominating and Corporate Governance Committee [2] - Dr. Huang brings extensive experience in biotechnology investment and corporate governance, having previously worked at Maxpro Ventures and Diamond Biofund [3][4][5] Company Overview - Apollomics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies that leverage the immune system and target specific molecular pathways [7] - The company's lead program is vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 clinical trial for non-small cell lung cancer and other advanced tumors [7]
Apollomics Announces Changes to its Board of Directors and Composition of Committees